Prescription pattern among patients having mild to moderate bronchial asthma using metered dose inhaler and dry powder inhaler in tertiary hospital in western india

Neha Akhoon, D. B. S. Brashier*

ABSTRACT

Background: Bronchial asthma is a syndrome characterized by airflow obstruction that manifests as shortness of breath, wheezing and cough. The treatment is tailored according to the severity of the disease. The drugs used for treatment of bronchial asthma include inhaled corticosteroids, beta-2 agonists, methylxanthines, leukotriene antagonists and mast cell stabilizers. Despite the availability of all these drugs, which are recommended for the treatment, not every patient achieves complete control of the disease. The reason behind this could be irrational prescribing of drugs for the treatment and errors in the technique of using inhaler devices. Though rational prescribing of drugs and correct technique for the use of inhaler can be improved by proper training of target population, but there is paucity of such data in our country.

Methods: This study was planned to monitor prescription pattern and errors in use of inhalation devices, in patients diagnosed as cases of mild to moderate bronchial asthma, attending Out Patient Department (OPD) of respiratory medicine of a tertiary hospital. A total of 207 patients were recruited and their prescription pattern and inhalation technique were assessed.

Results: The study showed that inhaled short acting β2-agonists and inhaled corticosteroids were the most commonly used drug groups, which were prescribed to all the patients in the study, followed by long acting β2-agonists, leukotriene antagonists and methylxanthines in decreasing order.

Conclusions: As a conclusion, the treating physicians were prescribing according to the laid down guidelines. It is concluded that such studies should be periodically done to ensure the adherence to the treatment guidelines.

Keywords: Bronchial asthma, Dry powder inhaler, Metered dose inhaler, Prescription pattern

INTRODUCTION

Chronic respiratory diseases, affecting the airways and other structures of lungs are common respiratory problem worldwide which include bronchial asthma as the most common disease, followed by chronic obstructive pulmonary disease (COPD), occupational lung diseases and pulmonary hypertension. The prevalence of bronchial asthma varies from 10-12% in adults and around 15% in children. It causes approximately 0.18 million deaths every year all over the world. Bronchial asthma is a syndrome characterized by airflow obstruction that manifests as shortness of breath, wheezing and cough. It is classified as intermittent, mild persistent, moderate persistent and severe persistent, according to the clinical features.3 The treatment is tailored according to the severity of the disease. The drugs used for treatment of bronchial asthma include inhaled corticosteroids, beta-2 agonists, methylxanthines, leukotriene antagonists and mast cell stabilizers. Despite the availability of all these drugs, which are recommended for the treatment, not every patient achieves complete control of the disease. One of
the possible reasons behind this could be, deviations from recommended guidelines for treatment. The United Kingdom National Review of asthma deaths has identified poor prescribing practices in patients with bronchial asthma, showing over-prescribing of short-acting reliever inhalers and insufficient provision of inhaled corticosteroid preventer medication and a failure by clinicians to adhere to British thoracic society (BTS) asthma guidelines. Another study showed that only 30.9% patients were using inhalers, whereas according to Global initiative for asthma (GINA) guidelines, inhalation therapy should be the first choice of treatment for bronchial asthma. Secondly, poor compliance of the patients, which could be due to adverse effects leading to under-treatment and hence poor control and further progression of the disease. In 2003, WHO published a report stating adherence rates to the treatment in developed countries is only about 50%.

Though rational prescribing of drugs and correct technique for the use of inhaler can be improved by proper training of target population, but there is paucity of such data in our country, hence this study was planned to monitor prescription pattern in patients diagnosed as cases of mild to moderate bronchial asthma, attending Out Patient Department (OPD) of respiratory medicine of a tertiary hospital.

METHODS

The study was conducted in a tertiary care hospital for a period of two years. The sample size was calculated to estimate 95% confidence interval for proportion of mild to moderate cases of asthma correctly using inhalation devices as per guidelines with 5% absolute error of margin. The sample size worked out to be 207 assuming that about 52% of mild to moderate cases of bronchial asthma are correctly following the prescription technique and assuming there are 420 patients of mild to moderate bronchial asthma registered in asthma clinics (according to the hospital data). This observational cross-sectional study was conducted to study prescription pattern in the patients included as per inclusion and exclusion criteria at a single visit to respiratory medicine out-patient department, after obtaining written informed consent and clearance from institutional ethics committee (IEC). Inclusion criteria was patients of age more than 18 years with mild to moderate bronchial asthma who were using inhalers. Exclusion criteria was patients suffering from severe bronchial asthma and patients concurrently suffering from illnesses other than bronchial asthma, including psychiatric diseases. Data regarding the patients’ socio-demographic information, educational status, history of illness and prescribed medications were recorded on a case record form.

RESULTS

A total of 207 patients were enrolled in the study from outpatient department of respiratory medicine from January 2015 to December 2015. Information regarding the patients and their treatment were tabulated (Table 1, 2).

| Demographic profile of study population. |
|------------------------------------------|
| Demographic characteristics | Number (%) |
| Gender | |
| Male | 113 (54.6%) |
| Female | 94 (45.4%) |
| Age | |
| 18 to 45 yrs | 111 (53.6%) |
| Above 45 yrs | 96 (46.4%) |
| Educational Status | |
| 12th and below | 97 (46.8%) |
| Graduate | 110 (53.1%) |

Table 2: Distribution of study population according to the medication administration.

| Route of administration | Drug group | Drug | No. of patients (%) |
|--------------------------|------------|------|---------------------|
| Oral | Methylxanthines | Theophylline | 37 (100) |
|                          | Leukotriene antagonists (LTRA) | Montelukast | 39 (100) |
| Inhaled medications | β2 agonist (SABA) | Levosalbutamol | 207 (100) |
|                          | Inhaled corticosteroid (ICS) | Budesonide | 91 |
|                          |                          | Beclomethasone | 22 |
|                          |                          | Fluticasone | 81 |
|                          |                          | Ciclesonide | 13 |
| Long acting β2 agonists (LABA) | Salmeterol | 40 |
|                          | Formoterol | 55 |

There were 113 (54.6%) males and 94 (45.4%) females. Age of patients included in the study was 18 years and above. Patients between 18 to 45 years were 111 (53.6%), whereas patients above 45 years were 96 (46.4%). Their mean age was 39 years.

Out of 207 patients, 97 (46.8%) did some schooling till twelfth standard, whereas 110 (53.1%) were graduates. Total 129 patients used pMDI, out of which, 120 (58%) used pMDI alone and 9 (4.3%) used pMDI with spacer and 78 (37.7%) were using DPI.

Table 3: Drugs primarily used for the treatment of bronchial asthma in study population.

| Category                  | Name of the drugs                        |
|---------------------------|------------------------------------------|
| Short acting beta-agonist | Levosalbutamol                           |
| Long acting beta-agonist  | Salmeterol, Formoterol                    |
| Corticosteroid            | Budesonide, Beclomethasone, Fluticasone, Ciclesonide |
| Methylxanthine            | Theophylline                              |
| Leukotriene antagonist     | Montelukast                               |
Similarly, patients ciclesonide, fluticasone and beclomethasone alone were received on combination of inhaled corticosteroids and a long acting beta agonist. Among patients on ICS, 20 (26.7%) were on budesonide, 10 (13.3%) on beclomethasone, 35 (46.7%) on fluticasone and 10 (13.3%) on ciclesonide.

Among those on combination of ICS and LABA, 33 (61.1%) were on salmeterol/fluticasone, 13 (24.1%) on formoterol/budesonide, 5 (9.2%) on formoterol/beclomethasone and 3 (5.6%) were on formoterol/ciclesonide. Among methylxanthines, theophylline was the only drug being prescribed, 17 patients were on it. Among leukotriene antagonists, montelukast was the only drug being prescribed, 13 patients were on it (Table 6).

Regarding the patients using pMDI, 75 were on only inhaled corticosteroids and 54 were on combination of inhaled corticosteroids and a long acting beta agonist. Among patients on ICS, 20 (26.7%) were on budesonide, 10 (13.3%) on beclomethasone, 35 (46.7%) on fluticasone and 10 (13.3%) on ciclesonide.

It was observed that the drugs which were primarily used in the treatment of bronchial asthma and their utilization pattern are as mentioned in Table 3.

None of the patients were on monotherapy. The number and percentage of patients, who received combination therapy i.e., two or more drug regimens, is shown in Table 4. Among the combination treatment regimens, 2-drug regimen was most commonly used (54.11%), while utilization of 3- and 4- drug regimen accounted for 14.49% and 31.40% respectively (Table 5).

Out of 207 patients, 129 used pMDI with or without spacer and 78 used DPI. Furthermore, out of those using pMDI, 75 were on only inhaled corticosteroids and 54 were on combination of inhaled corticosteroids and long acting beta agonist. Levosalbutamol, a short acting β2-agonist was prescribed to all the patients. Out of 91 patients on budesonide, 46 patients were on budesonide alone and 45 patients were on combination of budesonide and formoterol. Similarly, out of 22 patients on beclomethasone, 15 patients were on beclomethasone alone and 7 patients were on combination of beclomethasone and formoterol.

Out of 81 patients on fluticasone, 41 patients were on fluticasone alone and 40 patients were on combination of fluticasone and salmeterol. Out of 13 patients on ciclesonide, 10 patients were on ciclesonide alone and 3 patients were on combination of ciclesonide and formoterol. LABA (formoterol and salmeterol) were always used in combination with inhaled corticosteroids. Similarly, Theophylline, a methylxanthine and montelukast, a leukotriene antagonist were used only in combination.

Table 4: Anti-asthmatic drug utilization (individual/ combination).

| Category of drugs            | Therapy   | Individual | Combination | Total |
|------------------------------|-----------|------------|-------------|-------|
| Long acting beta-agonist     |           | 0          | 95          | 95    |
| Corticosteroids              | 112       | 95         | 207         |       |
| Methylxanthines              | 0         | 37         | 37          |       |
| Leukotriene antagonists      | 0         | 28         | 28          |       |

Table 5: Combination therapy in study population.

| Drug therapy                              | Number of patients (%) |
|-------------------------------------------|------------------------|
| Two-drug therapy (SABA+ ICS)              | 112 (54.11%)           |
| Three-drug therapy (SABA+ ICS+LABA)       | 30 (14.49%)            |
| Four-drug therapy (SABA+ ICS+LABA+Methylxanthines) | 65 (31.40%) |

Table 6: Prescription pattern in patients using pMDI with or without spacer.

| Medications       | No. of patients (%) |
|-------------------|---------------------|
| Inhaled Corticosteroids |                    |
| Budesonide        | 20 (26.7%)          |
| Beclomethasone    | 10 (13.3%)          |
| Fluticasone       | 35 (46.7%)          |
| Ciclesonide       | 10 (13.3%)          |
| Total             | 75 (100%)           |
| Combination of ICS + LABA   |                    |
| Fluticasone + Salmeterol | 33 (61.1%)         |
| Budesonide + Formoterol  | 13 (24.1%)          |
| Beclomethasone +Formoterol | 5 (9.2%)           |
| Ciclesonide + Formoterol  | 3 (5.6%)            |
| Total             | 54 (100%)           |
| Methylxanthines    | Theophylline        |
| Leukotriene antagonists | Montelukast     |

Table 7: Prescription pattern in patients using DPI.

| Medications       | Number of patients (%) |
|-------------------|------------------------|
| Inhaled corticosteroids |                    |
| Budesonide        | 26 (70.3%)            |
| Beclomethasone    | 5 (13.5%)             |
| Fluticasone       | 6 (16.2%)             |
| Total             | 37 (100%)             |
| Combination of ICS + LABA   |                    |
| Fluticasone + Salmeterol | 7 (17.1%)          |
| Budesonide + Formoterol  | 32 (78%)             |
| Beclomethasone +Formoterol | 2 (4.9%)           |
| Total             | 41 (100%)             |
| Methylxanthines    | Theophylline        |
| Leukotriene antagonists | Montelukast     |
Out of those using DPI, 37 patients were on only inhaled corticosteroids and 41 were on combination of inhaled corticosteroids and long acting beta agonist. Among patients on ICS, 26 (70.3%) were on budesonide, 5 (13.5%) on beclomethasone and 6 (16.2%) on fluticasone. Among those on combination of ICS and LABA, 7 (17.1%) were on salmeterol/fluticasone, 32 (78%) on formoterol/budesonide, 2 (4.9%) on formoterol/beclomethasone combination.

Among methylxanthines, theophylline was the only drug being prescribed, 20 patients were on it. Among leukotriene antagonists, montelukast was the only drug being prescribed, 15 patients were on it (Table 7).

**DISCUSSION**

A total of 207 patients who were diagnosed with mild to moderate bronchial asthma were recruited in the study and assessment of their prescription pattern and technique of inhalation devices was done.

This study showed that inhaled short acting β₂ agonists and inhaled corticosteroids were the most commonly used drug groups, which were prescribed to all the patients in the study, followed by long acting β₂ agonists, leukotriene antagonists and methylxanthines in decreasing order. Among pMDI users, the commonest inhaled corticosteroid used was fluticasone and commonest combination used was inhaled fluticasone and salmeterol, these findings were similar to previous study.9 Among DPI, commonest ICS used was budesonide rotacap and commonest combination was inhaled budesonide and formoterol, this was in concurrence with previous study.10 The prescription pattern for selection of drug class and route of administration is in accordance with the Global initiative for asthma and Britain thoracic society guidelines.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** The study was approved by the Institutional Ethics Committee

**REFERENCES**

1. Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison's principles of internal medicine. 18th Edi. McGraw Hill Professional; 2015:1036.
2. World Health Organization: Media centre. Bronchial asthma Factsheet No. 206. 2016. Available at http://http://www.who.int/mediacentre/factsheets/fs206/en.
3. Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment. Respir Med. 2006;100(7):1139-51.
4. Melani AS, Bonavita M, Cimenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930-8.
5. Pandey A, Tripathi P, Pandey RD. Prescription pattern in asthma therapy at Gorakhpur hospitals. Lung India: official organ of Indian Chest Society. 2010;27(1):8.
6. Jin J, Sklar G, Min Sen Oh V, Chuen Li. Factors affecting therapeutic compliance: A review from the patient’s perspective. Therapeutics and Clinical Risk Management. 2008;4(1):269-86.
7. Darba J, Ramírez G, García-Bujalance L, Torvinen S, Sánchez-de la Rosa R, Sicras A. Identification of factors involved in medication compliance: incorrect inhaler technique of asthma treatment leads to poor compliance. Patient Prefer Adherence. 2016:135.
8. Rafeeq MM, Murad H. Evaluation of drug utilization pattern for patients of bronchial asthma in a government hospital of Saudi Arabia. Niger J Clin Pract. 2017;20(9):1098-1105.
9. Suh DI, Yang HJ, Kim BS, Shin YH, Lee SY, Park G, Kim WK, Kim HB, Baek H, Kim JK, Kim JT. Asthma Severity and the Controller Prescription in Children at 12 Tertiary Hospitals. Allergy, asthma & immunology research. 2017;9(1):52-60.
10. Turi KN, Gebretadik T, Lee RL, Hartert TV, Evans AM. Seasonal patterns of Asthma medication fills among diverse populations of the United States. J Asthma. 2017 Sep 7:1-7.
11. Chou CL, Perng DW, Lin TL, Lin AM, Chen TJ, Wu MS, et al. Analysis of prescription pattern and guideline adherence in the management of asthma among medical institutions and physician specialties in Taiwan between 2000 and 2010. Clin Ther. 2015;37(10):2275-85.

**Cite this article as:** Akhoon N, Braslier DBS. Prescription pattern among patients having mild to moderate bronchial asthma using metered dose inhaler and dry powder inhaler in tertiary hospital in western india. Int J Basic Clin Pharmacol 2018;7:792-5.